Allurion Named Champion Partner' of World Obesity Federation.
Allurion named “Champion Partner” of the World Obesity Federation and official sponsor of World Obesity Day 2023
NATICK, Mass. – March 1st, 2023 - Allurion, a company dedicated to ending obesity, today announced that it has been named a World Obesity Champion by the World Obesity Federation and is an official sponsor of World Obesity Day 2023.
The objective of World Obesity Day 2023 is to increase awareness, encourage advocacy, improve policies, and share experiences around obesity. Two billion adults around the world struggle with excess weight and 650 million of those are living with obesity. By 2035, it is estimated that 1.9 billion people—or 1 in 4 people globally—will be living with obesity.
Dr. Shantanu Gaur, founder and CEO of Allurion, created the company with one mission: end obesity. By becoming a Champion Partner of the World Obesity Federation and a sponsor of World Obesity Day 2023, the company joins a coalition of stakeholders who are united in addressing the global obesity crisis and committed to building a healthier future for all.
“Obesity is a complex problem to solve, but it is not impossible. Collectively, we have the tools, knowledge and experience we need to help billions of people worldwide live healthier and happier lives,” says Dr. Gaur.
“At Allurion, we are excited to be joining the World Obesity Federation and its partners to raise awareness of obesity and develop cutting edge solutions to the problem. We are honored to be working with such a diverse group of experts who share our view that together, we can end obesity.”
“We know that the roots of obesity are complex and require urgent and collaborative action. We are therefore very excited to announce a new partnership with Allurion: they share our mission to end the challenges of obesity worldwide and have a strong foundation in helping to empower people who are living with overweight or obesity, through comprehensive approaches that last a lifetime,” says Johanna Ralston, CEO of the World Obesity Federation.
She adds: “For the World Obesity Federation and our members in more than 100 countries, a comprehensive approach is critical. We’re happy to count Allurion as one of our World Obesity Day champions and as a World Obesity Day sponsor that can work with us to help change the perception of obesity on a global level”.
Benoit Chardon, Chief Commercial Officer of Allurion, says: “The World Obesity Federation is the only global organization focused exclusively on obesity. Allurion already has a strong foundation in helping to empower people to make healthy choices that last a lifetime, but we look forward to surrounding ourselves with even more allies who are changing the conversation around excess weight and obesity around the world.”
About World Obesity Day
World Obesity Day is a unified day of action that calls for a cohesive, cross-sector response to the obesity crisis. Convened by World Obesity Federation (WOF) in collaboration with its members, it takes place on March 4 with the mission of increasing awareness, encouraging advocacy, improving policies, and sharing experiences. The first unified World Obesity Day was held in 2020.
Previous World Obesity Days have encouraged people to recognize the root causes of obesity, increase knowledge of the disease, tackle weight stigma, give voice to people with lived experience and act to improve the world’s understanding of obesity, and to help its prevention and treatment.
This year's campaign theme is 'Changing Perspectives: Let's Talk About Obesity'. This year’s goal is to harness the power of conversation and stories so that together, we can correct misconceptions about obesity and take effective, collective action. Because more talking, debating and sharing, can shift norms and transform health outcomes for everybody.
You can find out more about World Obesity Day and read about previous campaigns on the World Obesity website.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight-loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com
Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.
###
Media Contact
Cedric Damour
PR Manager
+33 7 84 21 02 20
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
NATICK, Mass. – December 2, 2024 – Allu...
Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
AllurionMeds is designed to...
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and...
Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15%...
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion...
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
In a...
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion...
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to its Board of Directors
Mr. Johns has...
Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight...
Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for...
Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer
NATICK, Mass. -- June 5, 2024 -- ...
Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s
Company also announces first...
Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean...
Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including
First-Ever 3-Year...
Allurion Expands Virtual Care Suite to the United States
Virtual Care Suite (VCS) is now available to license...
Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies
NATICK, Mass. -- Jan. 29, 2024 -- Alluri...
Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss
Allurion...
Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic...
Allurion Program led to resolution of type 2 diabetes, hypertension, and obstructive sleep apnea in just 4...
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion...
Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership
Company also announces addition...
Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon
AUDACITY trial to support FDA...
Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023
Research highlights...
Allurion Featured at the 2023 International Bariatric Club
Oxford University World Congress
Congress...
Allurion Introduces Coach Iris: A 24/7 Generative AI-Powered Weight Loss Coach
Powered by GPT and Fine-Tuned...
Allurion Announces Acceptance of Nine Scientific Presentations at IFSO 2023 World Congress
New data includes...
Allurion Debuts as a Publicly Traded Company on the NYSE
Allurion to commence trading on August 2, 2023 on the...
Allurion Announces New Additions to Board of Directors and Executive Leadership Team
Serial healthcare...
Allurion Presents New Data at the 2023 ASMBS Annual Meeting Demonstrating Mean Weight Reduction of Over 20%
P...
Allurion Announces Collaboration Agreement with Medtronic to Expand Access to AI-Powered Weight Loss Program
...Allurion to Participate in the Jefferies Healthcare Conference
NATICK, Mass. -- May 30, 2023 – Allurion, a...
First Multi-Center Study Combining the Allurion Program with GLP-1 Therapy Presented at the European Congress...
Allurion Presents Findings from Landmark Study Evaluating Fully Remote Weight Loss Coaching Program
Proprietar...
Allurion Announces Premium Tiers for the Virtual Care Suite and Launch of Proprietary “My Daily Action” Bundle...
Allurion Announces Appointment of MIT Distinguished Professor for AI and Health and MacArthur “Genius” Fellow
...Allurion, a Global Leader in Weight Loss Technology, to Become Publicly Listed Through Business Combination...
Allurion Technologies’ training awarded World Obesity Federation SCOPE accreditation
- Allurion’s gold...
Company reports 444% revenue growth from 2018 to 2021 and has also been named as one of MedTech Outlook’s Top...
- The world’s first and only procedureless gastric balloon receives approval from Brazilian Health...
New Delhi, 06 Sep 2022:
Allurion, a company dedicated to ending obesity, has launched the Allurion...
- Company launches the Allurion Iris™ Artificial Intelligence Platform and introduces Success Predictor, a...
Company announces approval of the Allurion Balloon in Canada, Mexico, Australia, and India where approximately...